These tumor samples were previously characterized by TCGA19, and key findings were the initial identification of transcriptional signatures associated with survival and the role of BRCA1/2 and CCNE1 aberrations, and an association between HRD and susceptibility to PARP inhibitors and improved survival. This evidence concerns the gene BRCA1 and neoplasm.